RSV is a leading respiratory virus causing hospitalization in infants and young children. Approximately 70% of children contract it in their first year, and most are infected at least once before two years old. Notably, 70-90% of hospitalizations involve healthy, full-term infants. Given this severe impact, many parents, like Hong Diep, 31, from Ho Chi Minh City, are asking about the effectiveness of RSV monoclonal antibodies, a new preventative option for children.

In young children, underdeveloped immune systems, narrow airways, and a weak cough reflex make them susceptible to severe RSV infections, which can rapidly lead to bronchiolitis, pneumonia, and respiratory failure. The World Health Organization (WHO) reports that RSV causes 3.6 million hospitalizations and 100,000 deaths annually in children under five years old globally. In the Western Pacific - Southeast Asia region, Vietnam ranks third for RSV infection rates in children, accounting for 35.5% of respiratory infections.

RSV circulates year-round in Vietnam, with a significant increase during the rainy and transitional seasons. Even children who stay home are vulnerable to infection, as adults or older children can carry the virus home, or it can spread via contaminated surfaces like toys, clothes, and bedding.

RSV monoclonal antibodies provide protection for infants and young children throughout the active disease season. Photo: Vecteezy

RSV monoclonal antibodies are biopharmaceuticals meticulously selected from individuals who have recovered from RSV infection, then multiplied and purified using modern technology. Extensive research indicates a strong safety profile for these products, making them suitable for infants and young children, especially those born prematurely, with low birth weight, or at high risk of severe progression.

Administering a monoclonal antibody dose is like providing a child with a "ready-made protective shield," offering immediate protection. This differs from a vaccine, which typically requires two to three weeks for the body to develop its own antibodies. Consequently, children are protected throughout the entire RSV season.

In Vietnam, Sanofi has introduced RSV monoclonal antibodies, available for infants up to 24 months old. Infants under 12 months receive one dose, with the dosage determined by weight. Children between 12 and 24 months old who are at high risk of RSV infection require two doses administered at two different sites on the same day.

Data demonstrates that RSV monoclonal antibodies reduce the risk of hospitalization due to lower respiratory tract infections by 82.7% and the risk of hospitalization due to severe infection by 75.3%, with effectiveness lasting the entire virus season.

Therefore, parents should proactively consider RSV monoclonal antibody treatment to help keep their children safe and healthy during their early years.

Doctor Le Thi Gam

Medical Manager, VNVC Vaccination System

Readers can submit vaccine-related questions for a doctor's response here.